Taken together, balanced phosphorylation and dephosphorylation of proteins are critical for physiology, and in particular, reverting PP2A activity ultimately to dephosphorylate tau or α-synuclein could be a promising therapeutic strategy for AD or PD treatment [265, 266]. The gene discussed is PTPA; the disease is Alzheimer disease.